Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 2Esophageal Squamous Cell Carcinoma 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Esophageal Neoplasms 1

Interventions

Cisplatin 136Radiotherapy 90Cetuximab 89pembrolizumab 65Fluorouracil 56Docetaxel 56Carboplatin 51Paclitaxel 44Radiotherapy, Intensity-Modulated 37Nivolumab 35durvalumab 19Erlotinib Hydrochloride 18Immunohistochemistry 16Radiation 13tremelimumab 12Gemcitabine 11Surgical Procedures, Operative 10Gene Expression Profiling 10Drug Therapy 10Biopsy 10Albumin-Bound Paclitaxel 10Chemotherapy, Adjuvant 9Capecitabine 9Bevacizumab 9atezolizumab 8Radiosurgery 8Polymerase Chain Reaction 8Neoadjuvant Therapy 8Ipilimumab 8130-nm albumin-bound paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Squamous Cell Carcinoma of Head and Neck × elgemtumab × Clear all
NCT01598077 2020-12-19

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

Novartis

Phase 1 Completed
54 enrolled
BreastGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡